Roche licenses Plexxikon's Phase I kidney disease candidate
Continuing a relationship that began two years ago, a new agreement has Roche licensing exclusive worldwide development and commercialization rights to Plexxikon Inc.'s (small-molecule therapeutics) Phase I Raf kinase inhibitor PLX5568 for polycystic kidney disease (PKD), an inherited condition characterized by the formation of renal cysts, which if enlarged, infected, or ruptured, could result in potential kidney failure. There is currently no marketed treatment for PKD.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.